Zhijie Deng

Oct 30, 2024 | mdpi.com | Zhijie Deng |Aejin Lee |Tao Lin |Sagarika Taneja

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 16, 2024 | onlinelibrary.wiley.com | Jian Jin |Zhijie Deng |LI YI CHEN |Chao Qian

Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Aug 16, 2024 | onlinelibrary.wiley.com | Zhijie Deng |LI YI CHEN |Chao Qian |Jing J. Liu

Introduction Small-molecule inhibitors and antibodies are two major classes of therapeutic modalities used to block the activity or downstream signaling of target proteins.1 On the other hand, small-molecule agonists typically activate target proteins that have protective functions, such as tumor suppressors.2 The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is a critical innate immune pathway that impacts all aspects of tumorigenesis, from malignant cell...